Highlights Newsletter 1

This newsletter presents you the following key sessions:

• Watch the video interview with professor Peter Schmid about the results of the phase III Impassion130 trial: clinically significant benefit in progression-free survival in patients with locally advanced or metastatic triple-negative breast cancer treated with atezolizumab + nab-paclitaxel

• Combining abiraterone acetate with radium-223 not recommended as first-line therapy for metastatic castration-resistant prostate cancer patients with bone metastases

• Improved progression-free survival of patients with HR+, HER2- advanced breast cancer treated with the PI3K inhibitor alpelisib

• Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC

• Gene expression profiles are associated with differential outcomes to atezolizumab plus bevacizumab or sunitinib as first-line treatment for metastatic renal cell carcinoma